<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00633529</url>
  </required_header>
  <id_info>
    <org_study_id>EMR 200068-200</org_study_id>
    <nct_id>NCT00633529</nct_id>
  </id_info>
  <brief_title>Safety of Adding IMO-2055 to Erlotinib + Bevacizumab in 2nd Line Treatment for Patients With NSCLC</brief_title>
  <official_title>Open-Label Phase 1b Study of Erlotinib Plus Bevacizumab and IMO-2055 in Patients With Non-Small Cell Lung Cancer Who Have Progressed Following Initial Chemotherapy for Advanced or Metastatic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>EMD Serono</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>EMD Serono</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the safety of the proposed Phase II dosage of the investigational drug IMO 2055
      when combined with erlotinib and bevacizumab in patients with previously treated advanced
      NSCLC.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Phase 1b study of escalating doses of weekly subcutaneous IMO-2055 combined with fixed
      standard dose regimens of oral erlotinib (daily) and IV bevacizumab (every 3 weeks) in
      patients with previously treated advanced NSCLC.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2007</start_date>
  <completion_date type="Actual">March 2011</completion_date>
  <primary_completion_date type="Actual">October 2010</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To determine the recommended dosage of IMO-2055 when combined with erlotinib and bevacizumab in patients with AJCC stage 3 or 4 histologically proven non-small cell lung cancer (NSCLC).</measure>
    <time_frame>Assessed on a weekly basis at patient visits.</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of weekly IMO-2055 combined with erlotinib plus bevacizumab using NCI CTCAE version 3.</measure>
    <time_frame>Assessed on a weekly basis at patient visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate potential drug-drug interactions via a PK study, specifically the effect of IMO-2055 on the PK of bevacizumab and the PK of erlotinib and also the effect of bevacizumab and erlotinib on the PK of IMO-2055.</measure>
    <time_frame>Assessed on a weekly basis at patient visits.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To investigate potential signs of efficacy using RECIST response rate in measurable patients and PFS in all patients.</measure>
    <time_frame>Assessed every six weeks.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Non-Small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>I</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single arm: triple combination</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>IMO-2055</intervention_name>
    <description>0.08, 0.16, or 0.32 mg/kg SC (subcutaneous) on days 1,8,and 15 of every 21 day cycle until evidence of progressive disease, unacceptable treatment-related toxicities, withdrawal of patient consent and/or Investigator decision to withdraw study therapy with documented reason, whichever occurs first.</description>
    <arm_group_label>I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion:

        Patients must satisfy all the following inclusion criteria in order to be eligible for the
        study:

          1. Signed written informed consent

          2. AJCC stage 3 or 4 histologically proven NSCLC not amenable to curative therapy and for
             whom erlotinib and bevacizumab therapy would be appropriate

          3. Radiological assessment within 21 days prior to inclusion, if measurable disease is
             present

          4. Age ≥ 18 years

          5. ECOG performance status 0 or 1

          6. Patient has received at least one standard platinum-containing chemotherapy regimen
             appropriate for his/her lung cancer, in the opinion of the investigator, prior to
             enrollment.

        Exclusion:

        Patients with any of the following will be excluded from participation in the study:

        Disease

          1. Squamous cell carcinoma, except for patients with no intrathoracic disease or small
             peripheral lesions only.

          2. Known central nervous system (CNS) metastases (Note: patients with brain metastases
             which have been controlled for ≥ 4 months without the use of steroid are eligible).

             Prior Treatments

          3. Less than 4 weeks between registration and the last receipt of chemotherapy,
             biotherapy, radiotherapy or major surgery

          4. Concurrent or planned hormonal agents such as replacement therapy, oral
             contraceptives, or anti-cancer therapy, e.g. Megace. (A prior history of such therapy
             is not exclusionary.)

          5. Administration of any investigational agent (therapeutic or diagnostic), including any
             investigational compound for the treatment of NSCLC, within 4 weeks prior to first
             study dosing Other Concomitant Medications

          6. High dose oral or intravenous corticosteroids. (Note: topical, inhaled and
             intra-articular corticosteroids are allowed. Prophylactic antihistamines are allowed
             before administration of bevacizumab

          7. Use of any medication which is a strong inhibitor or inducer of cytochrome P450
             isoform CYP3A4 (see Appendix 5)

          8. Therapeutic dosing with warfarin &gt;1 mg/day

          9. Chronic daily use of aspirin (&gt; 325 mg/day) or other full-dose NSAIDs with
             anti-platelet activity

         10. Inability to take oral medication or requirement for IV alimentation or total
             parenteral nutrition with lipids, or prior surgical procedures affecting absorption
             Laboratory

         11. The following laboratory results, within 10 days of first study drug administration:

               -  Hemoglobin ≤ 9.0 g/dL Absolute neutrophil count ≤ 1.5 x 109/L Platelet count ≤
                  100 x 109/L

               -  International Normalized Ratio (INR) &gt; 1.3 (only if the subject is on warfarin [&lt;
                  1 mg per day]) during 28 days prior to enrollment.

               -  aPTT &gt; Upper Limit of Normal (ULN) during 28 days prior to enrollment.

               -  Serum creatinine ≥ 1.5 x ULN and creatinine clearance (by Cockcroft-Gault
                  formula) &lt;60 mL/min

               -  Serum bilirubin ≥ 1.5 x ULN

               -  Proteinuria: UPC ≥ 1.0 or ≥ 2+ proteinuria by urine dipstick, unless a 24-hour
                  urine demonstrates &lt;1.0 g/24 hours

               -  ALT or AST ≥ 2.5 x ULN (≥ 5 x ULN if liver metastases)

               -  Alkaline phosphatase ≥ 2.5 x ULN

               -  Albumin ≤ 2.5 g/L

               -  Women of child bearing potential: positive pregnancy test (serum). Other
                  Conditions or Procedures

         12. Any clinically significant adverse events from any prior chemotherapy, surgery or
             radiotherapy which has not yet resolved to CTCAE v3.0 grade ≤ 1

         13. Known hypersensitivity to any oligodeoxynucleotide (ODN), EGFR-inhibitor or
             bevacizumab

         14. Serious, non-healing wound, ulcer or bone fracture

         15. Patients with a history or current neoplasm other than the entry diagnosis, except for
             curatively treated non-melanoma skin cancer or carcinoma in situ of the cervix and
             except for other cancers treated for cure and with a disease-free survival greater
             than 5 years.

         16. Pregnant or breast-feeding women

         17. Men or women of childbearing potential who refuse or who are unable to use an
             acceptable means of contraception

         18. History of clinically significant hemoptysis within 3 months prior to registration
             unless definitively treated with surgery or radiation

         19. Any medical conditions that would impose excessive risk to the patient, such as
             uncontrolled hypertension (systolic &gt;150 mmHg or diastolic &gt;100 mmHg per JNC 7
             guidelines, congestive heart failure NYHA Class 2-4, uncontrolled or unstable angina,
             myocardial infarction within the previous 6 months, ventricular arrhythmia, infection
             requiring parental or oral anti-infective treatment, any altered mental status or any
             psychiatric condition that would interfere with understanding the informed consent,
             uncontrolled seizures, chronic hepatitis or cirrhosis, known human immunodeficiency
             virus (HIV) infection, known hepatitis B surface antigen (HBsAg) positive or
             uncontrolled diabetes. (Note: testing for HIV infection of HBsAg is not part of the
             screening assessments performed by the central laboratory).

         20. Pre-existing autoimmune or antibody-mediated diseases, including, but not limited to,
             the following: systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis,
             Sjogren's syndrome and autoimmune thrombocytopenia

         21. Evidence of bleeding diathesis or coagulopathy or other serious or acute internal
             bleeding within 6 months prior to registration

         22. CNS bleeding; history or clinical evidence of CNS stroke (hemorrhagic or thrombotic)
             within the last 6 months

         23. History of allogeneic organ transplant

         24. Brain biopsy within 12 weeks of first study dosing

         25. Minor surgical procedure, central venous catheter placement, fine needle aspirations
             or core biopsy within 7 days prior to first study dosing

         26. Anticipation of need for a major surgical procedure during the course of the study
             Other

         27. Unwilling or unable to comply with the protocol for the duration of the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Breitfeld, MD</last_name>
    <role>Study Director</role>
    <affiliation>EMD Serono</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cancer Centers of Florida</name>
      <address>
        <city>Ocoee</city>
        <state>Florida</state>
        <zip>34761</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Indiana Cancer Centers</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New York Oncology Hematology P.C.</name>
      <address>
        <city>Albany</city>
        <state>New York</state>
        <zip>12206</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mary Crowley Medical Research Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Therapy and Research Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tyler Cancer Center</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Oncology Associates</name>
      <address>
        <city>Norfolk</city>
        <state>Virginia</state>
        <zip>23502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists</name>
      <address>
        <city>Vancouver</city>
        <state>Washington</state>
        <zip>98684</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yakima Valley Memorial Hospital/North Shore Cancer Lodge</name>
      <address>
        <city>Yakima</city>
        <state>Washington</state>
        <zip>98902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Smith, D., P. Conkling, D. Richards, C. Alemany, T. Boyd, L. Garbo, D. Loesch, D. Wages, A. Bexon, J. Murphy. Phase 1 Study of the Toll-like Receptor (TLR9) Agonist, IMO-2055, Combined with Erlotinib and Bevacizumab in Patients with Advanced or Metastatic non-Small Cell Lung Cancer. ECCO-ESMO Annual Meeting, 2009. Abstract 9.148.</citation>
  </results_reference>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 3, 2008</study_first_submitted>
  <study_first_submitted_qc>March 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 12, 2008</study_first_posted>
  <last_update_submitted>October 21, 2013</last_update_submitted>
  <last_update_submitted_qc>October 21, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 22, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1b</keyword>
  <keyword>Non-Small Cell Lung Cancer</keyword>
  <keyword>Advanced or Metastatic Disease</keyword>
  <keyword>Prior chemotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Erlotinib Hydrochloride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

